327 related articles for article (PubMed ID: 28714405)
1. Emerging Targets to Relieve Fat Stress-Induced Liver Diseases: UDCA, Tocotrienol, ω-3 PUFAs, and IgY Targeted NPC1L1 Cholesterol Transporter.
Cha JY; Park JM; Lee HJ; Bae JS; Han YM; Oh BC; Ko KH; Hahm KB
Curr Pharm Des; 2017; 23(27):3941-3951. PubMed ID: 28714405
[TBL] [Abstract][Full Text] [Related]
2. Amelioration of non-alcoholic fatty liver disease with NPC1L1-targeted IgY or n-3 polyunsaturated fatty acids in mice.
Bae JS; Park JM; Lee J; Oh BC; Jang SH; Lee YB; Han YM; Ock CY; Cha JY; Hahm KB
Metabolism; 2017 Jan; 66():32-44. PubMed ID: 27923447
[TBL] [Abstract][Full Text] [Related]
3. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.
Kim JK; Lee KS; Lee DK; Lee SY; Chang HY; Choi J; Lee JI
Exp Mol Med; 2014 Dec; 46(12):e127. PubMed ID: 25523099
[TBL] [Abstract][Full Text] [Related]
4. [Non-alcoholic fatty liver disease and steatohepatitis].
Pár G; Horváth G; Pár A
Orv Hetil; 2013 Jul; 154(29):1124-34. PubMed ID: 23853345
[TBL] [Abstract][Full Text] [Related]
5. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
6. [Non-alcoholic fatty liver disease and hepatocellular carcinoma - 2016].
Pár A; Pár G
Orv Hetil; 2016 Jun; 157(25):987-94. PubMed ID: 27287838
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.
Namisaki T; Noguchi R; Moriya K; Kitade M; Aihara Y; Douhara A; Nishimura N; Takeda K; Okura Y; Kawaratani H; Takaya H; Seki K; Yoshiji H
J Gastroenterol; 2016 Feb; 51(2):162-72. PubMed ID: 26190501
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
Massoud O; Charlton M
Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
[TBL] [Abstract][Full Text] [Related]
9. Future therapy for non-alcoholic fatty liver disease.
Issa D; Patel V; Sanyal AJ
Liver Int; 2018 Feb; 38 Suppl 1():56-63. PubMed ID: 29427492
[TBL] [Abstract][Full Text] [Related]
10. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
Caldwell S
Clin Mol Hepatol; 2017 Jun; 23(2):103-108. PubMed ID: 28494529
[TBL] [Abstract][Full Text] [Related]
11. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.
Ganesh S; Rustgi VK
Clin Liver Dis; 2016 May; 20(2):351-64. PubMed ID: 27063274
[TBL] [Abstract][Full Text] [Related]
12. Non-alcoholic fatty liver disease as a cause and consequence of cardio-metabolic complications. Role of the ursodeoxicholic acid in the pharmacotherapy.
Maevskaya MV; Ivashkin VT; Ivashkin KV; Lunkov VD; Liusina EO; Zozula VN; Leshchenko VI
Ter Arkh; 2019 Mar; 91(2):109-117. PubMed ID: 31094181
[TBL] [Abstract][Full Text] [Related]
13. Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe in NAFLD/NASH treatment.
Yoshida M
Curr Vasc Pharmacol; 2011 Jan; 9(1):121-3. PubMed ID: 21044016
[TBL] [Abstract][Full Text] [Related]
14. The metabolic syndrome and chronic liver disease.
Rosselli M; Lotersztajn S; Vizzutti F; Arena U; Pinzani M; Marra F
Curr Pharm Des; 2014; 20(31):5010-24. PubMed ID: 24320032
[TBL] [Abstract][Full Text] [Related]
15. Natural antioxidants for non-alcoholic fatty liver disease: molecular targets and clinical perspectives.
Salomone F; Godos J; Zelber-Sagi S
Liver Int; 2016 Jan; 36(1):5-20. PubMed ID: 26436447
[TBL] [Abstract][Full Text] [Related]
16. The Future of Nonalcoholic Fatty Liver Disease Treatment.
Mazhar K
Med Clin North Am; 2019 Jan; 103(1):57-69. PubMed ID: 30466676
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic Fatty Liver Disease in Children: Hepatic and Extrahepatic Complications.
Selvakumar PKC; Kabbany MN; Nobili V; Alkhouri N
Pediatr Clin North Am; 2017 Jun; 64(3):659-675. PubMed ID: 28502444
[TBL] [Abstract][Full Text] [Related]
18. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
19. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].
Scorletti E; Bhatia L; McCormick KG; Clough GF; Nash K; Calder PC; Byrne CD;
Contemp Clin Trials; 2014 Mar; 37(2):301-11. PubMed ID: 24556343
[TBL] [Abstract][Full Text] [Related]
20. Current and future pharmacologic treatment of nonalcoholic steatohepatitis.
Banini BA; Sanyal AJ
Curr Opin Gastroenterol; 2017 May; 33(3):134-141. PubMed ID: 28346237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
